| Document |
Document Title |
|
WO/2022/013378A1 |
The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such...
|
|
WO/2022/008923A1 |
The present invention relates to the use of compounds of Formula (I) as herbicides, wherein Z, W, X1-X4, R1, F2, R3, R4, m and n are as defined herein. The invention further relates to agrochemical compositions comprising a compound of F...
|
|
WO/2022/011338A2 |
The present invention relates to novel compounds that modulate the activity of one or more kinases, such as TYK2 or mutants thereof. The compounds, which may be kinase inhibitors or activators, are useful for treating autoimmune diseases...
|
|
WO/2022/005414A1 |
The invention is related to new 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2a-j) and 7 new 1,2,4-triazole (3a-g) derivatives and synthesis of these compounds, in vitro anticancer activity studies and molecular docking and in silico ADME st...
|
|
WO/2021/258272A1 |
The present invention provides compounds of Formula (I) which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising th...
|
|
WO/2021/257020A1 |
Within the scope of the invention, 15 novel 3-[2-(1,3-benzodioxole-5-yl)ethyl)]-6-aryl-7H-1,2,4-triazolo
[3,4-b]-1,3,4-thiadiazine derivatives were synthesized. The cytotoxic and apoptotic effects of some synthesized compounds in human l...
|
|
WO/2021/249800A1 |
The present invention relates to substituted [1,2,4]triazole compounds of formula I and the N-oxides and the salts thereof, to the use of said compounds and methods for combating phytopathogenic fungi and to seeds coated with at least on...
|
|
WO/2021/249468A1 |
Disclosed is a method for preparing a chlorinated compound, and specifically disclosed is a method for preparing a compound represented by formula (I).
|
|
WO/2021/245533A1 |
Present invention relates to development of compound of formula (Ia) for treatment of inflammatory bowel diseases. Invention also relates to pharmaceutical composition comprising therapeutically effective compound of formula (Ia) for tre...
|
|
WO/2021/245590A1 |
The present invention relates to an improved process for the preparation of triazole derivatives such as ravuconazole and isavuconazole.
|
|
WO/2021/247217A1 |
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament f...
|
|
WO/2021/247732A1 |
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...
|
|
WO/2021/243480A1 |
A triazole sulfonamide derivative, a preparation method for same, and applications thereof. Specifically, related are the triazole sulfonamide derivative as represented by formula (I) or a stereoisomer of the triazole sulfonamide derivat...
|
|
WO/2021/238881A1 |
The present invention discloses a series of triazolone compounds, and specifically discloses a compound and a pharmaceutically acceptable salt thereof as shown in formula (V).
|
|
WO/2021/204923A9 |
A compound of formula (I) for use in the treatment of a Coronaviridae virus infection. A novel compound of formula (I), and a process for preparing the compound.
|
|
WO/2021/236775A1 |
The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein R1, R3, L, Y, and B1 are as defined in the specification. Compounds having Formula I are SHP2 protein degraders useful for the...
|
|
WO/2021/233994A1 |
The present invention provides SOCE inhibitors that are useful as therapeutic agents in a variety of applications. The present invention also relates to pharmaceutical compositions, products and kits comprising such SOCE inhibitors, and ...
|
|
WO/2021/230382A1 |
Provided is a plant disease control agent which has low toxicity to humans and animals and high safety in handling and which exhibits excellent antimicrobial effects, even at a low application dose, on a large number of microorganisms ca...
|
|
WO/2021/208602A9 |
The present invention provides a benzotriazole derivative corrosion inhibitor, a preparation method therefor and the use thereof. The preparation method comprises the following steps: placing benzotriazole, diethanolamine and formaldehyd...
|
|
WO/2021/226009A1 |
Provided herein are processes for synthesizing intermediates useful in preparing Mcl-1 inhibitors. In particular, provided herein are processes for synthesizing compound F, or a salt thereof, wherein R1 and OPG2 are described herein. Com...
|
|
WO/2021/221836A1 |
Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substi...
|
|
WO/2021/219813A1 |
Compounds of formula (1) comprising a pleuromutilin backbone with a triazole based side-group at C22 are provided. The compounds can be used for treatment of bacterial infections and fungal infections. Importantly, infections caused by m...
|
|
WO/2021/221011A1 |
The present invention provides, as a stable and easy-to-handle tyrosine modifier, a compound that is represented by general formula (I), (II), or (III) (in the formula, A represents a conjugated ring, L represents a linker or the like ha...
|
|
WO/2021/214463A1 |
The present invention relates to a stable fungicidal composition comprising at least one conazole fungicide and at least one weak acid. In particular, the present invention provides a composition comprising a conazole fungicide, a weak a...
|
|
WO/2021/216940A1 |
A method of producing a triazoline-containing compound, the method comprising reacting an alkene, which comprises at least one a C=C double bond, with an azido compound, which comprises an azide anion having the chemical formula N3 -, wh...
|
|
WO/2021/209689A1 |
A composition comprising a compound or a salt thereof is disclosed. A method for treating a plant curatively and/or preventively against at least one plant pathogenic virus and/or against sweet potato virus disease (SPVD), as well as use...
|
|
WO/2021/209473A1 |
The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2021/197107A1 |
There is provided the use of an N-alkylpyrrolidone to inhibit the crystallization of a fungicidally active triazole in a liquid formulation. Preferably, an N-alkylpyrrolidone of the general formula (I) is employed: wherein R is an alkyl ...
|
|
WO/2021/186406A1 |
The present invention provides a co-crystal of sulfentrazone and a triazinone herbicide and process for preparation thereof. The present invention also provides an agrochemical composition comprising said co-crystal and process of prepar...
|
|
WO/2021/188769A1 |
Compounds that inhibit HIF-2a, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse arr...
|
|
WO/2021/186855A1 |
Provided is a novel method for detecting an indicator of T-cell lymphoma. This method for detecting an indicator of T-cell lymphoma comprises a step for detecting acetylated tubulin in T cells collected from a subject.
|
|
WO/2021/188523A1 |
The invention relates to methods of treating cell proliferative disorders. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
|
|
WO/2021/182530A1 |
A novel method for producing an azole derivative represented by general formula (I) comprises: a step for obtaining a bromohydrin derivative through reaction between an organometallic reagent generated from 1-bromo-2-chloro-4-(4-chloroph...
|
|
WO/2021/181122A1 |
The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein X, Y, R1, R2, R3 and R4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders as...
|
|
WO/2021/177442A1 |
The present invention provides a plant disease control agent which has low toxicity to humans and animals and excellent handling safety, while exhibiting an excellent controlling effect on a wide range of plant diseases and a high antiba...
|
|
WO/2021/168561A1 |
The present invention provides solvent-limited processes for the preparation of an existing crystalline solid form of an active pharmaceutical ingredient comprising mixing, in the presence of solvent vapour, of a solid active pharmaceuti...
|
|
WO/2021/165735A1 |
Compound of formula (I) able to modulate Store Operated Calcium Entry (SOCE). The disclosure also relates to compositions and uses of compounds of formula (I) for treatment of disease condition depending on increased/ decreased activity ...
|
|
WO/2021/161789A1 |
The present invention provides a pressure-measuring sheet set, pressure-measuring sheet, method for manufacturing a pressure-measuring sheet set, method for manufacturing a pressure-measuring sheet, dispersion, dispersion set, and microc...
|
|
WO/2021/162633A1 |
Disclosed herein is a process for the manufacture of a cationic fused N-heterocyclic ring system, comprising reaction of a compound of formula (I): with a base and with a material FF or only with a base to provide a compound of formula (...
|
|
WO/2021/162054A1 |
The purpose of the present invention is to provide a type 2 ryanodine receptor (RyR2) activity inhibitor having an excellent effect of inhibiting RyR2 activity.　An RyR2 activity inhibitor comprising a compound represented by formula (Î...
|
|
WO/2021/155050A1 |
Provided herein are kinase modulators, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease, d...
|
|
WO/2021/155277A1 |
Disclosed are immune cell-selective small molecule IMPDH inhibitor compounds and methods of their synthesis and use to treat proliferative disorders.
|
|
WO/2021/153794A1 |
The present invention provides a method of controlling soybean rust fungus that has an F129L amino acid substitution in the mitochondrial cytochrome b protein. The compound represented by formula (I) can be used to control soybean rust f...
|
|
WO/2021/147521A1 |
A triazole derivative, a preparation method therefor, and a use thereof, relating to the technical field of organic synthetic drugs. The structure of the triazole derivative is shown in formula I, wherein R1 and R2 in formula I are H, Cl...
|
|
WO/2021/147484A1 |
Disclosed in the present invention are a 2-(1,2,4-triazolyl)benzoyl arylamine active compound for inhibiting a wheat take-all pathogen, and a preparation method therefor. The active compound has a structure as shown in formula I. R1, R3,...
|
|
WO/2021/142953A1 |
A thioether triazole compound or a pesticidally acceptable salt thereof, a composition and use thereof. The compound has a structure of formula (I). The compound has higher biological activity than known compounds, can effectively kill b...
|
|
WO/2021/142155A1 |
The present disclosure provides processes for preparing 1,2,3-triazole-4-carboxylic acid related compounds of formulae (I) and (II) via a Suzuki coupling reaction. The Suzuki coupling reaction is achieved by coupling a compound of formul...
|
|
WO/2021/134242A1 |
A new crystal form of flucarbazone-sodium, a preparation method thereof and the use thereof in controlling the growth of undesired plants.
|
|
WO/2021/136431A1 |
Disclosed is a series of benzo[d][1,2,3]triazole ether compounds, and specifically disclosed are a compound shown in formula (I) and pharmaceutically acceptable salts thereof.
|
|
WO/2021/138540A1 |
Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.
|
